Treatment of bone metastases in breast cancer: An update

被引：1

作者：

Myra F. Barginear

Catherine H. Van Poznak

机构：

[1] Monter Cancer Center of the North Shore-LIJ Cancer Institute, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY 11042

[2] University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-5848

来源：

Current Breast Cancer Reports | 2012年 / 4卷 / 4期

关键词：

Antiresorptive agents; Bisphosphonates; Bone metastases; Bone modifying agents; Bone turnover markers; Breast cancer; Denosumab; Imaging; Interventions; Monitoring; Radiation therapy; Radiopharmaceuticals; Skeletal metastases; Skeletal related events; SREs; Surgery; Treatment;

D O I：

10.1007/s12609-012-0089-1

中图分类号：

学科分类号：

摘要：

Bone is the most common site of breast cancer metastases. When breast cancer has metastasized to bone, it is considered an incurable disease. Osseous metastases are associated with significant morbidities including pain, pathological fractures, hypercalcemia of malignancy, and spinal cord compression. In this setting, the palliative goals of care include preventing skeletal related events, managing complications, reducing bone pain, and improving quality of life. Antiresorptive agents such as bisphosphonates have been the mainstay of bone-directed treatment, along with radiation therapy, and surgery. Most recently, RANKL-inhibitors have become another tool in the treatment of bone metastases. This review discusses bone-modifying agents and other targeted interventions in breast cancer patients with skeletal metastases. © Springer Science+Business Media, LLC 2012.

引用

页码：257 / 263

页数：6

共 47 条

[1]

Jemal A., Bray F., Center M.M., Et al., Global cancer statistics, CA Cancer J Clin, 61, pp. 69-90, (2011)

[2]

DeSantis C., Siegel R., Bandi P., Jemal A., Breast cancer statistics, 2011, CA Cancer J Clin, 61, pp. 409-18, (2011)

[3]

Guise T., Examining the metastatic niche: Targeting the microenvironment, Semin Oncol, 37, SUPPL. 2, (2010)

[4]

Jensen A.O., Jacobsen J.B., Norgaard M., Et al., Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in denmark, BMC Cancer, 11, (2011)

[5]

Pavlakis N., Schmidt R., Stockler M., Bisphosphonates for breast cancer, Cochrane Database Syst Rev, (2005)

[6]

Wong M.H., Pavlaki N., Optimal management of bone metastases in breast cancer patients, Breast Cancer Targets Ther, 3, pp. 35-60, (2011)

[7]

Kohno N., Aogi K., Minami H., Et al., Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial, J Clin Oncol, 23, pp. 3314-21, (2005)

[8]

Ruiz-Borrego M.L.A., Martin M., Calvo L., Bayo J., RamosM Adrover E., Et al., On behalf of the spanish breast cancer research group (geicam) san sebastián de los reyesmadrid spain, Breast Cancer Res Treatment, 94, SUPPL., (2005)

[9]

Safety And Efficacy Of Zoledronic Acid In Patients With Breast Cancer With Metastatic Bone Lesions, (2012)

[10]

Amadori D A.M., Alessi B., Gianni L., Ibrahim T., Farina G., Gaion F., Et al., Zoom: A prospective, randomized trial of zoledronic acid (zol

← 1 2 3 4 5 →